Catalyst
Slingshot members are tracking this event:
GW Pharma (GWPH) to Initiate Phase 2 Placebo-Controlled Study in H2 2017 Evaluating CBDV (GWP42006) in Autism Spectrum Disorders
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GWPH |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2018
Occurred Source:
http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-announces-preliminary-results-phase-2a-study
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Trial Initiation, Placebo-controlled Study, Cbdv, Gwp42006, Autism Spectrum Disorders
